
	Moderate COVID-19	Severe COVID-19	Relative Risk (95% CI); [*; p-value]	Total
Number	70.8% (80 / 113)	29.2% (33 / 113)		113
Age (years)	62.66 ± 16.1	63.67 ± 19.3	[n.s.]	62.96 ± 17.0
Sex				
Male	45% (36 / 80)	48.48% (16 / 33)	1.07 (.70 - 1.65)	46.02% (52 / 113)
Female	55% (44 / 80)	51.52% (17 / 33)	.94 (.64 - 1.38)	53.98% (61 / 113)
Ethnicity				
American Indian / Alaskan Native	0% (0 / 80)	0% (0 / 33)		0% (0 / 113)
Asian	1.25% (1 / 80)	0% (0 / 33)		0.88% (1 / 113)
Black / African American	27.5% (22 / 80)	33.33% (11/33)	1.21 (.67 - 2.21)	29.2% (33 / 113)
Native Hawaiian / Pacific Islander	0% (0 / 80)	0% (0 / 33)		0% (0 / 113)
White	53.75% (43 / 80)	54.55% (18 / 33)	1.01 (.70 - 1.47)	53.98% (61 / 113)
Hispanic	12.5% (10 / 80)	12.12% (4 / 33)	.97 (.33 - 2.87)	12.39% (14 / 113)
Multiple	0% (0 / 80)	0% (0 / 33)		0% (0 / 113)
Unknown	5% (4 / 80)	0% (0 / 33)	n.c.	3.54% (4 / 113)
BMI	376 (17 66)	0,0 (0,7 35)	THE.	5.5478 (17 115)
<18.5	0% (0 / 80)	6.06% (2 / 33)	n.c.	1.77% (2 / 113)
18.5-24.9	21.25% (17 / 80)	9.09% (3 / 33)	.43 (.13 - 1.36)	17.7% (27 113)
25.0-29.9	, , ,	24.24% (8 / 33)	.75 (.38 - 1.47)	30.09% (34 / 113)
30-35	32.5% (26 / 80) 27.5% (22 / 80)	30.3% (10 / 33)	1.10 (.59 - 2.06)	28.32% (32 / 113)
>35	18.75% (22 / 80)	30.3% (10 / 33)	1.10 (.59 - 2.06)	28.52% (52 / 113) 22.12% (25 / 113)
	16.75% (15/60)	30.3% (10 / 33)	1.02 (.81 - 3.22)	22.12% (25 / 113)
COVID Risk Factors	27 504 (22 (22)			
None	27.5% (22 / 80)	30.3% (10 / 33)	1.10 (.59 - 2.06)	28.32% (32 / 113)
Cancer Treatment within 1 year	7.5% (6 / 80)	15.15% (5 / 33)	2.02 (.66 - 6.16)	9.73% (11 / 113)
Chronic Heart Disease	27.5% (22 / 80)	24.24% (8 / 33)	.88 (.44 - 1.78)	26.55% (30 / 113)
Hypertension	53.75% (43 / 80)	48.48% (16 / 33)	.90 (.60 - 1.35)	52.21% (59 / 113)
Chronic Lung Disease (asthma, COPD, ILD)	26.25% (21 / 80)	18.18% (6 / 33)	.69 (.31 - 1.56)	23.89% (27 / 113)
Immunosupression	11.25% (10 / 80)	6.06% (2 / 33)	.52 (.12 - 2.29)	9.73% (12 / 113)
Solid Organ Transplant	6.25% (4 / 80)	3.03% (1 / 33)	.60 (.07 - 5.16)	4.42% (5 / 113)
HIV ⁺ (with anti-viral treatment; CD4 > 400)	2.5% (2/80)	0% (0 / 33)	n.c.	1.77% (2 / 113)
Other (Multiple Sclerosis, Rheumatoid Arthritis, Scleroderma, Cirrhosis)	3.75% (3 / 80)	3.03% (1 / 33)	1.21 (.11 - 12.91)	3.54% (4 / 113)
Presenting Symptoms				
Headache	56.9% (33 / 58)	47.37% (9 / 19)	.83 (.49 - 1.41)	54.55% (42 / 77)
Objective Fever (> 100.3 °F / 37.9 °C)	64.29% (36 / 56)	65% (13 / 20)	1.01 (.69 - 1.47)	64.47% (49 / 76)
Cough	77.19% (44 / 57)	65% (13 / 20)	.84 (.59 - 1.20)	74.03% (57 / 77)
Dyspnea	64.41% (38/59)	75% (15 / 20)	1.16 (.85 - 1.60)	67.09% (53 / 79)
Rhinorrhea	30.36% (17 / 56)	35.29% (6 / 17)	1.16 (.55 - 2.48)	31.51% (23 / 73)
Sore Throat	27.59% (16 / 58)	22.22% (4 / 18)	.81 (.31 - 2.10)	26.32% (20 / 76)
Nausea	48.28% (28 / 58)	41.18% (7 / 17)	.85 (.46 - 1.60)	46.67% (35 / 75)
Vomitting	31.03% (18 / 58)	27.78% (5 / 18)	.90 (.39 - 2.07)	30.26% (23 / 76)
Diarrhea	50% (29 / 58)	35.29% (6 / 17)	.71 (.35 - 1.41)	44% (33 / 75)
Abdominal Pain	31.03% (18 / 58)	5.88% (1 / 17)	.19 (.03 - 1.32)	25.33% (19 / 75)
Hypogeusia	37.04% (20 / 54)	33.33% (5 / 15)	.90 (.41 - 1.99)	36.23% (25 / 69)
Anosmia	31.37% (16 / 51)	33.33% (5 / 15)	1.06 (.47 - 2.42)	31.82% (21 / 66)
All Cause Mortality	3.75% (3 / 80)	27.27% (9 / 33)	7.27 (2.10 - 25.19)***; [p = .0002]	10.62% (21/ 00)


Table 1: Basic Demographics for COVID-19 Cohort. Unless otherwise noted, relative risks were not statisticity significant. Moderate (Clinical Score 1-3) and severe (Cinica Score 4-5) disease status were assigned as described in Methods. Percentages of sub-group (moderate or severe) are shown for each category with respective counts in parenthesis. Average age was calculated with accompanying sample standard deviation. Ethnicity and BMI were extracted from most recent electronic medical record (EMR) data. Select COVID-19 Risk Factors were scored by a clinical infectious disease physician. Presenting symptoms were recorded primarily through direct interview with patient or surrogate.

[&]quot;--": No data available; [n.s.]: Not statistically significant; "n.c": Not calcuable; "---": Chi-Square χ^2 (1, N = 113) = 13.62, p = .0002

Extended data Fig1: Age and BMI cohort distributions and Select Medications distribution

D






Changes in IL-6, according to tocilizumab, after controlling, age, ICU admission and days from symptom onset, accounting for multiple observations per person (GEE).

(022)			
Covariate	Coefficient	95% CI	
Tocilizumab	0.55	0.07, 1.04	
ICU admission	0.48	-0.02, 0.99	
Days from symptom onset	-0.02	-0.04, -0.003	
Age	0.01	0.0003, 0.02	
This washing and older the half dates to old	II C b	form and a later to although the	


Changes in T cell count, according to age, ICU admission and days from symptom onset, accounting for multiple observations per person (GEE).

Covariate	Coefficient	95% CI
ICU admission	-13.43	-19.32, -7.55
Days from symptom onset	-0.15	-0.41, 0.11
Age	-0.16	-0.33, 0.02


Extended Data Fig. 2: Overview of cellular immune changes in COVID-19 patients




Extended Data Fig3: Overview of cytokine and chemokine profiles of COVID-19 patients




Extended Data Fig3: Overview of cytokine and chemokine profiles of COVID-19 patients







Extended Data Fig.5: T cell imune profile in moderate vs. severe patients



Extended Fig 6: Early cytokine pofile distinguishes moderate and severe outcomes



Extended Data Fig 7: Distribution of days from symptom onset stratified by collection time point



Extended Data Fig 8: Risk of death according to biomarkers levels

Risk of death:

